$CLPT
ClearPoint Neuro, Inc. Stock $clpt

$clpt Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000128555023000020 Filed on March 01, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$5.433M	$5.174M	$20.55M
YoY Change	7.99%	20.83%	26.09%
Cost Of Revenue	$2.231M	$1.858M	$7.020M
YoY Change	24.99%	87.11%	40.18%
Gross Profit	$3.202M	$3.316M	$13.53M
YoY Change	-1.36%	0.82%	19.84%
Gross Profit Margin	58.94%	64.09%	65.84%
Selling, General & Admin	$2.958M	$4.161M	$9.611M
YoY Change	8.27%	-8.29%	9.7%
% of Gross Profit	92.38%	125.48%	71.03%
Research & Development	$3.023M	$3.624M	$10.89M
YoY Change	19.34%	32.55%	21.25%
% of Gross Profit	94.41%	109.29%	80.51%
Depreciation & Amortization	$129.0K	$20.00K	$244.0K
YoY Change	50.0%	-56.52%	53.46%
% of Gross Profit	4.03%	0.6%	1.8%
Operating Expenses	$5.981M	$7.785M	$20.51M
YoY Change	13.6%	7.07%	15.55%
Operating Profit	-$5.712M	-$4.469M	-$16.33M
YoY Change	47.83%	12.23%	22.12%
Interest Expense	$114.0K	$84.00K	$81.00K
YoY Change	7.55%	-151.22%	-91.68%
% of Operating Profit
Other Income/Expense, Net	-$11.00K	$0.00	-$22.00K
YoY Change	-200.0%	-100.0%	-65.08%
Pretax Income	-$5.609M	-$4.385M	-$16.43M
YoY Change	41.68%	5.69%	14.05%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$5.609M	-$4.385M	-$16.44M
YoY Change	41.68%	5.69%	14.05%
Net Earnings / Revenue	-103.24%	-84.75%	-79.97%
Basic Earnings Per Share	-$0.23		-$0.68
Diluted Earnings Per Share	-$0.23	-$0.18	-$0.68
COMMON SHARES
Basic Shares Outstanding	24.61M shares		24.18M shares
Diluted Shares Outstanding	24.58M shares		24.18M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.74M	$37.49M	$37.49M
YoY Change	-36.09%	-30.72%	-30.72%
Cash & Equivalents	$21.80M	$27.60M	$27.62M
Short-Term Investments	$9.943M	$9.874M	$9.874M
Other Short-Term Assets	$1.764M	$1.723M	$1.723M
YoY Change	364.21%	239.17%	239.17%
Inventory	$9.808M	$9.303M	$9.303M
Prepaid Expenses
Receivables	$2.678M	$2.665M	$2.665M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$45.99M	$51.18M	$51.18M
YoY Change	-20.73%	-17.31%	-17.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$949.0K	$806.0K	$2.701M
YoY Change	33.85%	49.54%	-2.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$131.0K	$131.0K	$581.0K
YoY Change	39.36%	4.8%	-9.78%
Total Long-Term Assets	$4.262M	$4.310M	$4.310M
YoY Change	13.5%	16.83%	16.83%
TOTAL ASSETS
Total Short-Term Assets	$45.99M	$51.18M	$51.18M
Total Long-Term Assets	$4.262M	$4.310M	$4.310M
Total Assets	$50.25M	$55.49M	$55.49M
YoY Change	-18.65%	-15.39%	-15.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.352M	$272.0K	$272.0K
YoY Change	40.1%	-36.3%	-36.3%
Accrued Expenses	$3.421M	$5.450M	$5.450M
YoY Change	38.67%	49.4%	49.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.054M	$6.788M	$6.788M
YoY Change	52.38%	42.82%	42.82%
LONG-TERM LIABILITIES
Long-Term Debt	$9.907M	$9.893M	$9.893M
YoY Change	0.57%	0.56%	0.56%
Other Long-Term Liabilities	$1.706M	$1.922M	$1.922M
YoY Change	-22.94%	-12.76%	-12.76%
Total Long-Term Liabilities	$11.61M	$11.82M	$11.82M
YoY Change	-3.75%	-1.88%	-1.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.054M	$6.788M	$6.788M
Total Long-Term Liabilities	$11.61M	$11.82M	$11.82M
Total Liabilities	$17.67M	$18.60M	$18.60M
YoY Change	10.16%	10.77%	10.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$156.0M	-$150.0M
YoY Change	13.13%	12.0%
Common Stock	$188.6M	$187.3M
YoY Change	2.69%	2.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$32.58M	$36.89M	$36.89M
YoY Change
Total Liabilities & Shareholders Equity	$50.25M	$55.49M	$55.49M
YoY Change	-18.65%	-15.39%	-15.39%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$5.609M	-$4.385M	-$16.44M
YoY Change	41.68%	5.69%	14.05%
Depreciation, Depletion And Amortization	$129.0K	$20.00K	$244.0K
YoY Change	50.0%	-56.52%	53.46%
Cash From Operating Activities	-$5.700M	-$3.065M	-$16.20M
YoY Change	32.56%	-13.71%	27.56%
INVESTING ACTIVITIES
Capital Expenditures	$138.0K	$254.0K	$253.0K
YoY Change	100.0%	-768.42%	50.6%
Acquisitions
YoY Change
Other Investing Activities		$12.00M	-$9.590M
YoY Change
Cash From Investing Activities	-$138.0K	$11.75M	-$10.74M
YoY Change	-25.41%	-31010.53%	6290.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$5.000K	222.0K	$409.0K
YoY Change	-266.67%	362.5%	-99.13%
NET CHANGE
Cash From Operating Activities	-$5.700M	-3.065M	-$16.20M
Cash From Investing Activities	-$138.0K	11.75M	-$10.74M
Cash From Financing Activities	-$5.000K	222.0K	$409.0K
Net Change In Cash	-$5.823M	8.903M	-$26.49M
YoY Change	30.82%	-351.36%	-177.9%
FREE CASH FLOW
Cash From Operating Activities	-$5.700M	-$3.065M	-$16.20M
Capital Expenditures	$138.0K	$254.0K	$253.0K
Free Cash Flow	-$5.838M	-$3.319M	-$16.45M
YoY Change	33.62%	-5.55%	27.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001285550
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-34822
CY2022	dei	Entity Registrant Name EntityRegistrantName	CLEARPOINT NEURO, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2394628
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	120 S. Sierra Ave.
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92075
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Solana Beach
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	City Area Code CityAreaCode	888
CY2022	dei	Local Phone Number LocalPhoneNumber	287-9109
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2022	dei	Trading Symbol TradingSymbol	CLPT
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	272000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24609284	shares
CY2022	dei	Auditor Firm AuditorFirmId	677
CY2022	dei	Auditor Name AuditorName	Cherry Bekaert LLP
CY2022	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27615000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54109000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	9874000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2665000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2337000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9303000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4938000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1723000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	508000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	51180000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	61892000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	806000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1895000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2241000	usd
CY2022Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	450000	usd
CY2021Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	519000	usd
CY2022Q4	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	1028000	usd
CY2021Q4	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	265000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	131000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	125000	usd
CY2022Q4	us-gaap	Assets Assets	55490000	usd
CY2021Q4	us-gaap	Assets Assets	65581000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	272000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	427000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2824000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2604000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2065000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	537000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	561000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	507000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1066000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	678000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6788000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4753000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1532000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1939000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	390000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	264000	usd
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	9893000	usd
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	9838000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	18603000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	16794000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24578983	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24578983	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23665991	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23665991	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	246000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	237000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	187008000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	182482000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150367000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133932000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36887000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48787000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55490000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65581000	usd
CY2022	us-gaap	Revenues Revenues	20551000	usd
CY2021	us-gaap	Revenues Revenues	16299000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	7020000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	5176000	usd
CY2022	us-gaap	Gross Profit GrossProfit	13531000	usd
CY2021	us-gaap	Gross Profit GrossProfit	11123000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10894000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9281000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9358000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7217000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9611000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7999000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-16332000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-13374000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	usd
CY2022	us-gaap	Interest Expense InterestExpense	81000	usd
CY2021	us-gaap	Interest Expense InterestExpense	973000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16435000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14410000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24181854	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24181854	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20734236	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20734236	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2377000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	14974000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46785000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2078000	usd
CY2021	clpt	Warrant And Option Exercises Cash And Cashless WarrantAndOptionExercisesCashAndCashless	465000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	224000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	599000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14410000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48787000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4126000	usd
CY2022	clpt	Warrant And Option Exercises Cash And Cashless WarrantAndOptionExercisesCashAndCashless	268000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	477000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	336000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16435000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36887000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16435000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14410000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-117000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	202000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	244000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	159000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4126000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2078000	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	325000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	55000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	100000	usd
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	533000	usd
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	533000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	284000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	211000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	658000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4421000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1714000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1216000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	264000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	66000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1591000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1285000	usd
CY2022	clpt	Lease Liabilities LeaseLiabilities	-541000	usd
CY2021	clpt	Lease Liabilities LeaseLiabilities	-432000	usd
CY2022	clpt	Increase Decrease From Contract With Customer Deferred Revenue IncreaseDecreaseFromContractWithCustomerDeferredRevenue	515000	usd
CY2021	clpt	Increase Decrease From Contract With Customer Deferred Revenue IncreaseDecreaseFromContractWithCustomerDeferredRevenue	165000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16167000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12697000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	253000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	168000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	893000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	21590000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	12000000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10736000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-168000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46785000	usd
CY2022	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	268000	usd
CY2021	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	465000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	477000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	224000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	336000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	599000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	409000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46875000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26494000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34010000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54109000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20099000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27615000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54109000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	523000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	597000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100000	usd
CY2021	clpt	Net Transfers Of Reusable Components From Loaned Systems NetTransfersOfReusableComponentsFromLoanedSystems	100000	usd
CY2022	clpt	Net Transfers Of Reusable Components From Loaned Systems NetTransfersOfReusableComponentsFromLoanedSystems	100000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-3100000	usd
CY2021Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	200000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	200000	usd
CY2022Q4	clpt	Number Of Companies NumberOfCompanies	50	company
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16200000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration Risks and Other Risks and Uncertainties</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company holds substantially all its cash and cash equivalents on deposit with financial institutions in the U.S. that are insured by the Federal Deposit Insurance Corporation or in U.S. government debt securities. At December 31, 2022, the Company had approximately $1.8 million in bank balances that were in excess of the insured limits.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, one customer accounted for 19% of accounts receivable, and at December 31, 2021, one customer accounted for 15% of accounts receivable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One pharmaceutical customer, a related party who is a stockholder, a noteholder, and who has a representative on the Company's Board of Directors (see Note 7), for whom the Company provides hardware, software, clinical services, and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 15% of total revenue for the year ended December 31, 2022, and of 18% total revenue for the year ended December 31, 2021. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to granting credit, the Company performs credit evaluations of its customers’ financial condition, and generally does not require collateral from its customers. The Company will provide an allowance for doubtful accounts when collections become doubtful. The allowance for doubtful accounts at December 31, 2022 and 2021 was $0.1 million and $0.3 million, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; dependence on third-party collaboration, license and joint development partners; changes in general economic conditions and interest rates; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.</span></div>
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1800000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated statement of operations for the year ended December 31, 2022 contains certain items formerly classified as sales and marketing expenses and research and development that have been reclassified to cost of revenue. Additionally, in 2022, the Company is classifying share-based compensation in the same income statement line items as the cash compensation paid to those employees, rather than in general and administrative expense. The accompanying consolidated statement of operations for the year ended December 31, 2021 has been conformed to the 2022 presentation.</span></div>
CY2022	us-gaap	Revenues Revenues	20551000	usd
CY2021	us-gaap	Revenues Revenues	16299000	usd
CY2022Q4	clpt	Deferred Contract Costs DeferredContractCosts	300000	usd
CY2022Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	500000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27600000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54100000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	9900000	usd
CY2022Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	6513000	usd
CY2021Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	2718000	usd
CY2022Q4	clpt	Software Licenses SoftwareLicenses	210000	usd
CY2021Q4	clpt	Software Licenses SoftwareLicenses	210000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2580000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2010000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9303000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4938000	usd
CY2022Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	450000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	usd
CY2021Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	519000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	9753000	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	5457000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2575000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2428000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1769000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1889000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	806000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	486000	usd
CY2021Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	200000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	10000000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	107000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	9893000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	200000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.088
CY2022	us-gaap	Lease Cost LeaseCost	500000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	594000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	582000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	500000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2162000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	69000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2093000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	3400000	usd
CY2022	clpt	Contractual Obligation In The Ordinary Course Of Business Term ContractualObligationInTheOrdinaryCourseOfBusinessTerm	P1Y
CY2022	clpt	License And Collaboration Agreement Minimum Purchase Commitment Term LicenseAndCollaborationAgreementMinimumPurchaseCommitmentTerm	P5Y
CY2022	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	2100000	usd
CY2022	clpt	License And Collaboration Agreement Minimum Purchase Commitment Term LicenseAndCollaborationAgreementMinimumPurchaseCommitmentTerm	P5Y
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4126000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2078000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4126000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2078000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1350473	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.69
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.10
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	147723	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.91
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.45
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	69910	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	43.27
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1398286	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.69
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M9D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5328000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1133621	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.12
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y5M19D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5113000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1398286	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y1M9D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5328000	usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	291220	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.38
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	147723	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	169987	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	5.16
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	4291	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	10.33
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	264665	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.19
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0307
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0095
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M4D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M9D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9002
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5720
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.21
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.48
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	56561	shares
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	clpt	Percentage Valuation Allowance Deferred Tax Assets PercentageValuationAllowanceDeferredTaxAssets	1
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	800000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4800000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3472000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3060000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	250000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1560000	usd
CY2022	clpt	Effective Income Tax Reconciliation Permanent Adjustments EffectiveIncomeTaxReconciliationPermanentAdjustments	17000	usd
CY2021	clpt	Effective Income Tax Reconciliation Permanent Adjustments EffectiveIncomeTaxReconciliationPermanentAdjustments	114000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	646000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	18000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-9000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	111000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1999000	usd
CY2022	clpt	Effective Income Tax Rate Reconciliation Net Operating Loss Write Off Amount EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteOffAmount	1599000	usd
CY2021	clpt	Effective Income Tax Rate Reconciliation Net Operating Loss Write Off Amount EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteOffAmount	1649000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	831000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4865000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26574000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26379000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1591000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2083000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	349000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	860000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1584000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	97000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	69000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30195000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29391000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30156000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29324000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	39000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	67000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	39000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	67000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30200000	usd

Files In Submission

Name	View Source	Status
0001285550-23-000020-index-headers.html	Edgar Link	pending
0001285550-23-000020-index.html	Edgar Link	pending
0001285550-23-000020.txt	Edgar Link	pending
0001285550-23-000020-xbrl.zip	Edgar Link	pending
clearpointneuroinc-formofr.htm	Edgar Link	pending
clpt-20221231.htm	Edgar Link	pending
clpt-20221231.xsd	Edgar Link	pending
clpt-20221231x10kex21.htm	Edgar Link	pending
clpt-20221231x10kex231.htm	Edgar Link	pending
clpt-20221231x10kex311.htm	Edgar Link	pending
clpt-20221231x10kex312.htm	Edgar Link	pending
clpt-20221231x10kex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
clpt-20221231_cal.xml	Edgar Link	unprocessable
clpt-20221231_lab.xml	Edgar Link	unprocessable
clpt-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clpt-20221231_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
clpt-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLPT
ClearPoint Neuro, Inc. Stock $clpt

2023 Q1 Form 10-K Financial Statement

#000128555023000020 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT ClearPoint Neuro, Inc. Stock $clpt

2023 Q1 Form 10-K Financial Statement

#000128555023000020 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT
ClearPoint Neuro, Inc. Stock $clpt